Novavax (NVAX) – Press Releases
-
Shah Capital nominates two highly qualified independent director candidates for Novavax
-
Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024
-
Novavax to Participate in TD Cowen's 44th Annual Health Care Conference
-
Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
-
Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement
-
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024
-
Novavax to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
-
Novavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan
-
Novavax's Updated COVID-19 Vaccine Now Authorized in Canada
-
Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization
-
Novavax Makes Changes to Executive Leadership Team to Enhance Focus on Delivery of Strategic Priorities
-
Novavax to Participate in Jefferies London Healthcare Conference
-
Novavax to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Operational Highlights on November 9, 2023
-
Novavax's Updated COVID-19 Vaccine Now Approved in the EU
-
Novavax's Updated Nuvaxovid™ COVID-19 Vaccine Receives Positive CHMP Opinion in the EU
-
Novavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine Nuvaxovid™ ▼ in United Kingdom
-
Novavax's Prototype COVID-19 Vaccine Nuvaxovid™ Receives Full Approval in Singapore
-
Novavax COVID-19 Vaccine Doses Available at Major Retail Pharmacies Across the U.S.
-
Novavax Advances Science Supporting Protein-based Vaccine Technology at IDWeek 2023 and World Vaccine Congress Europe 2023
-
Novavax Launches Choose to Protect™ Campaign to Educate Public About Importance of Updated COVID Vaccination this Fall
-
Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.
-
Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
-
Novavax to Participate in Upcoming September Conferences
-
Novavax's Updated Protein-based XBB COVID Vaccine Induced Neutralizing Responses Against Emerging Subvariants, Including EG.5.1 and XBB.1.16.6
-
Novavax Reports Second Quarter 2023 Financial Results and Operational Highlights
-
Novavax to Host Conference Call to Discuss Second Quarter 2023 Financial Results and Operational Highlights on August 8, 2023
-
Novavax's Nuvaxovid™ Receives Full Marketing Authorization in the EU for the Prevention of COVID
-
Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall
-
Novavax Announces Adjournment of 2023 Annual Meeting of Stockholders to July 11, 2023
-
Novavax Announces Agreement with Bill & Melinda Gates Medical Research Institute to Include Matrix-M™ Adjuvant as Potential Component in Vaccine Research
-
Novavax to Participate in the Jefferies Global Healthcare Conference
-
Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU
-
Access to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore
-
Novavax Reports First Quarter 2023 Financial Results and Operational Highlights
-
Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses
-
Novavax to Participate in the BofA Securities 2023 Health Care Conference
-
Novavax to Host Conference Call to Discuss First Quarter 2023 Financial Results and Operational Highlights on May 9, 2023
-
Novavax Grows Presence at World Vaccine Congress 2023 and 33rd European Congress of Clinical Microbiology & Infectious Diseases
-
Novavax to Participate in TD Cowen's 43rd Annual Health Care Conference
-
Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
-
Novavax Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
-
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 28, 2023
-
U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine
-
Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
-
Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster
-
Novavax Names John C. Jacobs as New President & Chief Executive Officer
-
Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates
-
Novavax Announces Closing of $175.25 Million Offering of Convertible Senior Notes Due 2027 and $74.75 Million Public Offering of Common Stock
-
Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes
-
Novavax Announces Pricing of $65 Million Public Offering of Common Stock
Back to NVAX Stock Lookup
